The GLP-1 Analogue Exenatide Improves Hepatic and Muscle Insulin Sensitivity in Diabetic Rats: Tracer Studies in the Basal State and during Hyperinsulinemic-Euglycemic Clamp

Abstract EN

Objective.

Glucagon-like peptide-1 (GLP-1) analogues (e.g., exenatide) increase insulin secretion in diabetes but less is known about their effects on glucose production or insulin-stimulated glucose uptake in peripheral tissues.

Methods.

Four groups of Sprague-Dawley rats were studied: nondiabetic (control, C); nondiabetic + exenatide (C + E); diabetic (D); diabetic + exenatide (D + E) with diabetes induced by streptozotocin and high fat diet.

Infusion of 3-3H-glucose and U-13C-glycerol was used to measure basal rates of appearance ( R a ) of glucose and glycerol and gluconeogenesis from glycerol (GNG).

During hyperinsulinemic-euglycemic clamp, glucose uptake into gastrocnemius muscles was measured with 2-deoxy-D-14C-glucose.

Results.

In the diabetic rats, exenatide reduced the basal R a of glucose ( P < 0.01 ) and glycerol ( P < 0.01 ) and GNG ( P < 0.001 ).

During the clamp, R a of glucose was also reduced, whereas the rate of disappearance of glucose increased and there was increased glucose uptake into muscle ( P < 0.01 ) during the clamp.

In the nondiabetic rats, exenatide had no effect.

Conclusion.

In addition to its known effects on insulin secretion, administration of the GLP-1 analogue, exenatide, is associated with increased inhibition of gluconeogenesis and improved glucose uptake into muscle in diabetic rats, implying improved hepatic and peripheral insulin sensitivity.